Mardi Dier
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
-
Start not stated–2022-11-15
Company network
Recorded roles and earnings-call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Madrigal Pharmaceuticals, Inc. (MDGL) | Executive Vice President and Chief Financial Officer | $566,042 | $6,085,089 |
| 2024 | Madrigal Pharmaceuticals, Inc. (MDGL) | Executive Vice President and Chief Financial Officer | $464,679 | $8,751,912 |
| 2022 | Ultragenyx Pharmaceutical Inc. (RARE) | Former Chief Financial Officer and Executive Vice President | $607,346 | $4,436,756 |
| 2021 | Ultragenyx Pharmaceutical Inc. (RARE) | Former Chief Financial Officer and Executive Vice President | $561,539 | $3,331,874 |
| 2020 | Ultragenyx Pharmaceutical Inc. (RARE) | Former Chief Financial Officer and Executive Vice President | $116,346 | $6,120,642 |
Recent activity
Earnings-call appearances and filed executive appointments or departures, newest first.